Frequently Asked Questions About IXSBF

What does InNexus Biotechnology, Inc. do?

InNexus Biotechnology, Inc. (IXSBF) operates in the Medical - Pharmaceuticals industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is IXSBF's market cap?

InNexus Biotechnology, Inc. (IXSBF) has a market capitalization of approximately $12,627, as of November 7, 2025, based on the most recent share price and shares outstanding.

Does IXSBF pay a dividend?

No — InNexus Biotechnology, Inc. (IXSBF) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is IXSBF profitable?

InNexus Biotechnology, Inc. (IXSBF) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

IXSBF (InNexus Biotechnology, Inc.) is no longer actively trading.

This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.

IXSBF

InNexus Biotechnology, Inc.

OTC·Medical, Pharmaceuticals · Healthcare

$0.00$0.00+0.00%

Market cap$12.63K·Market closed·Nov 7 9:00 PM UTC

Price Chart

$0.00+$0.00 (+0.00%)today

+9,900.00%CAGR +151.73%

Select date range

FromTo

Jan 28, 2005Aug 27, 2021 → Aug 27, 2026· 5.0 yrsAug 27, 2026

Key Metrics

IXSBF does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueC$0.00

Net Income−C$4.24M

Net Margin—

Operating Cash Flow−C$476.84K

Capital ExpendituresC$0.00

Free Cash Flow−C$476.84K

Return on Equity—

Return on Invested Capital0.0%

Net DebtC$6.69M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for IXSBF and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how IXSBF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IXSBF and 80,000+ other tickers.

About InNexus Biotechnology, Inc.

InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology. This DXL platform is designed to boost the therapeutic efficacy of conventional monoclonal antibody treatments by strengthening their binding to target antigens, amplifying their effector functions, and endowing them with novel properties. InNexus's development portfolio features several investigational therapies: DXL625: A monoclonal antibody currently in late-stage pre-clinical…

CEO: Angela Giannoccaro
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Exchange: OTC
Website: www.innexusbiotech.com/

Peers

Peers Tab

BMGP

Biomagnetics Diagnostics Corp.

Cap

$1.3K

WCUI

Wellness Center USA, Inc.

Latest News

News Tab

No recent news available.

Frequently Asked Questions About IXSBF

What does InNexus Biotechnology, Inc. do?: InNexus Biotechnology, Inc. (IXSBF) operates in the Medical - Pharmaceuticals industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is IXSBF's market cap?: InNexus Biotechnology, Inc. (IXSBF) has a market capitalization of approximately $12,627, as of November 7, 2025, based on the most recent share price and shares outstanding.
Does IXSBF pay a dividend?: No — InNexus Biotechnology, Inc. (IXSBF) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is IXSBF profitable?: InNexus Biotechnology, Inc. (IXSBF) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.